KZR (STOCKS)
Kezar Life Sciences, Inc. Common Stock
$6.300000
+0.000000 (+0.00%)
Prev close: $6.300000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Christopher J. Kirk
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $46.40M
- Employees
- 55
- P/E (TTM)
- -0.75
- P/B (TTM)
- 0.56
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
1
Strong Buy
3
Buy
6
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-1.53 | $-2.10 | +0.5686 | +27.09% |
|
Jun 2025 (Q2)
|
$-1.87 | $-2.41 | +0.5426 | +22.49% |
|
Mar 2025 (Q1)
|
$-2.27 | $-2.63 | +0.3611 | +13.72% |
|
Dec 2024 (Q4)
|
$-2.77 | $-2.91 | +0.1430 | +4.91% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $65.51M |
| Research and Development | $44.71M |
| Other Operating Expenses | $20.80M |
| Operating Income/Loss | -$65.51M |
| Income/Loss From Continuing Operations After Tax | -$61.71M |
| Income/Loss From Continuing Operations Before Tax | -$61.71M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$61.71M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$61.71M |
| Net Income/Loss Available To Common Stockholders, Basic | -$61.71M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$8.44 |
| Diluted Earnings Per Share | -$8.44 |
| Basic Average Shares | 7,316,607 |
| Diluted Average Shares | 7,316,607 |
| Assets | $97.73M |
| Current Assets | $94.50M |
| Noncurrent Assets | $3.23M |
| Fixed Assets | $2.18M |
| Other Non-current Assets | $1.05M |
| Liabilities | $14.75M |
| Current Liabilities | $13.38M |
| Accounts Payable | $911.00K |
| Wages | $2.12M |
| Other Current Liabilities | $10.35M |
| Noncurrent Liabilities | $1.37M |
| Equity | $82.98M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $82.98M |
| Liabilities And Equity | $97.73M |
| Net Cash Flow From Operating Activities | -$56.64M |
| Net Cash Flow From Operating Activities, Continuing | -$56.64M |
| Net Cash Flow From Investing Activities | $64.60M |
| Net Cash Flow From Investing Activities, Continuing | $64.60M |
| Net Cash Flow From Financing Activities | -$3.83M |
| Net Cash Flow From Financing Activities, Continuing | -$3.83M |
| Exchange Gains/Losses | -$47.00K |
| Net Cash Flow | $4.08M |
| Net Cash Flow, Continuing | $4.12M |
| Comprehensive Income/Loss | -$61.69M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$61.76M |
| Other Comprehensive Income/Loss | $52.30M |
| Other Comprehensive Income/Loss Attributable To Parent | -$93.00K |